aktiv8 identifies activity across the entire life sciences ecosystem — companies, assets, trials, catalysts, funding, regulatory milestones — and connects the right people to act on it. Investors, BD teams, CROs, CDMOs, advisors, and technology vendors. Powered by Hakase.
Whether you're partnering an asset, investing in a company, winning a CRO client, advising on a mandate, scouting an acquisition, or selling technology into pharma — every connection turns on timing. Yet the intelligence to act is scattered across expensive databases, ClinicalTrials.gov, EDGAR, FDA calendars, and press releases. Teams spend hours assembling a view that's already stale, and end up reacting to opportunities they read about in the news — after everyone else.
aktiv8 replaces that patchwork with one real-time intelligence and connection workspace — for BD and corporate development, VC and crossover investors, CROs and CDMOs, regulatory consultants, technology vendors, and the banks and advisors who serve them all.
Every company, pipeline, asset, catalyst, trial, funding round, investor, and signal — in a single, continuously-refreshed view. Every source timestamped.
Hakase routes every question to the best model, grounds every answer in verified corpus data, and stress-tests high-stakes outputs with a second model. Tuned for biotech intelligence — not a general-purpose chatbot.
From a PDUFA date or a funding round to a verified contact and a personalised, signal-aware message — without leaving the platform.
aktiv8 tracks activity at every stage — so you connect at the right moment, not after it's passed.
License early, before competition drives up the price. Spot emerging science before it becomes a headline.
In-license post-readout, co-develop, or win the CRO contract before the RFP goes out.
Co-promotion, distribution, regulatory tooling — a narrow window that closes fast.
Acquire, distribute, co-promote, or supply services to a newly commercial company at peak need.
Partner on a new indication, track a competitor's biosimilar programme, or flag lifecycle risk early.
How different stakeholders use aktiv8 to connect faster and act first. See all use cases →
A crossover fund tracks 40 oncology companies across Phase 1/2. aktiv8 flags that three hit primary endpoints in the same week — before any press release. HAKASE identifies which has the strongest IP and no lead investor yet. The fund term-sheets before the round is announced.
A mid-size CRO monitors 200 pre-Phase 2 companies. aktiv8 signals that a rare disease biotech just closed a Series A. HAKASE notes their lead asset has no CRO named. The BD director reaches out with a tailored proposal six weeks before the formal RFP is issued.
A biotech receives FDA approval on a Friday. By Monday they need a shortlist of co-promotion partners. HAKASE returns 12 companies with the right focus, no conflicting product, and active BD mandates. Verified contacts are pulled in one click. Three meetings are booked by Wednesday.
A regulatory consultancy targets GCC pharma companies seeking US or EU market entry. HAKASE returns every company in the region with a marketed product, an active pipeline, and no named regulatory partner for international filings. 15 high-fit targets in under two minutes.
An investment bank receives a buy-side mandate for a large pharma seeking CNS acquisitions. aktiv8 filters for Phase 2/3 CNS assets, funded in the last 24 months, with no announced acquirer. HAKASE generates a one-page brief on each. A 20-company longlist is ready for the next morning.
A large pharma's corp dev team monitors 30 potential targets. aktiv8 alerts them when one runs a Phase 3 miss — before the stock reacts. HAKASE flags the company's cash runway is 9 months. The corp dev lead calls the CEO the same afternoon.
Finding the company is the easy part. aktiv8 gives you the verified email to reach the right decision-maker, drafts a personalised, signal-aware message with AI, and tracks every follow-up like a CRM — all from one platform.
Hakase continuously pulls catalysts, trial updates, funding rounds, and press — matched to companies the moment they happen.
Every signal resolves to a full company profile — pipeline, funding, catalysts, and an AI-identified BD angle. Know why this company, why now.
Email-verified decision-maker contacts, plus a personalised signal-aware draft from Hakase. Tone controls. One click to send.
Every outreach is logged. Move deals through stages, assign owners, set next actions. Opportunities don't go cold.
A multi-model orchestration layer built exclusively for life sciences intelligence. A supervisor routes each task — match, report, question, outreach — to the right model, grounds every answer in verified corpus facts, and stress-tests high-stakes outputs with a second model before you see them.
The best model for each task, routed by a supervisor — with automatic fallback if any provider degrades.
Every output is built strictly from verified corpus facts. Fabricated figures are stripped before you see them.
High-stakes outputs like deal matches are generated by one model and stress-tested by another.
Every report and match becomes proprietary training data. The engine sharpens over time — on our data, never yours.
AI matchmaking scores in- and out-licensing fit across the corpus and proposes the deal archetype.
Map investor mandates, portfolios, and the right way in — then reach the decision-maker.
A live FDA/PDUFA calendar with AI-flagged BD angles on every event.
Investment-grade company, investor, and catalyst reports generated on demand.
Verified emails plus signal-aware, tone-controlled drafts — sent from the platform, no exporting.
A built-in CRM logs every outreach, stage, and next action. Promote any signal to a deal in one click.
A natural-language analyst across your entire corpus, with cited answers and sources.
Find partners, licensees, and acquirers — timed to catalysts and readouts.
Screen companies, monitor trial readouts, time entry before the round is announced.
Identify clients before they issue an RFP. Reach the right contact the week they raise.
Build target lists and company briefs overnight for buy-side and sell-side mandates.
Monitor acquisition targets continuously — act at the right valuation, not at the banker's call.
Find every company expanding into a new market before they've appointed a regulatory partner.
Identify which pharma and biotech companies need your product — filtered by stage, activity, and signal.
Track every trial in your disease area, monitor pipeline gaps, and connect with investigators.
| Without aktiv8 | With aktiv8 |
|---|---|
| Multiple expensive databases | One workspace |
| Hours of manual research | One-click AI reports |
| Spot deals in the news | Spot deals first |
| Records, but no contact or no email | Verified emails — reach decision-makers directly |
| Export, switch tools, write from scratch | AI-drafted, signal-aware email in one click |
| No memory of your outreach | Built-in CRM tracks every follow-up to close |
| Static, stale data | Live and timestamped |
See aktiv8 on your own market in a 30-minute walkthrough.